

INDEX

A

- Affinity DNA-binding assay
 - biotinylated DNA..... 81
- Affinity purification
 - FLAG..... 451
- Affymetrix Exon Array..... 508, 513, 515, 516
- Affymetrix gene chip system 6
- Agarose gel electrophoresis
 - denaturing alkaline agarose gel
 - electrophoresis 314–315
 - denaturing polyacrylamide gel
 - electrophoresis 316–317
 - native..... 292, 309, 314
- A/G PLUS agarose 124, 129, 246, 257–260, 566, 575
- ANRO. *See* Array-based nuclear run-on
- APB. *See* Azido phenacyl bromide
- Apoptosis assay..... 485
- Array-based nuclear run-on (ANRO) analysis
 - human A549 lung adenocarcinoma epithelial cells.... 508
 - human H9 stem cells..... 508
 - in human Jurkat T cells..... 508
 - human P493–6 B lymphocytes..... 508
 - and mouse embryonic fibroblasts..... 508
- Azidophenacyl bromide (APB) 370, 375–376, 384, 393, 395

B

- Baculovirus 447, 449, 451–460, 462
- β -galactosidase activity 30–31, 33, 38, 41, 43, 47
- Bromine-conjugated UTP (BrUTP)..... 520–521, 528
- BRPF1/2/3 (bromodomain PHD
 - finger protein 1, 2 or 3)..... 447
- BrUTP. *See* Bromine-conjugated UTP

C

- Calmodulin column..... 239, 245–246
- cAMP. *See* cyclic AMP
- cDNA
 - methylation by EcoP15I enzyme..... 542
 - purification 509
 - synthesis 194, 508, 512–513, 539, 540, 549–551

C/EBP β

- a candidate regulator region of the SOCS–3 promoter
 - in vascular endothelial cells..... 205, 212
- Ceres database
 - data mining tools
 - UME6 TFBS..... 222–224
 - nucleosome positioning in the promoter region of the
 - UBC4 gene..... 219
 - promoter features of *GAL1* gene..... 219
- ChAP. *See* Chromatin affinity purification
- ChEC. *See* Chromatin endogenous cleavage
- ChIC. *See* Chromatin immunocleavage
- ChIP. *See* Chromatin immunoprecipitation
- Chromatin affinity purification (ChAP)
 - ChAP-chip..... 240–242, 250, 251
 - CUX1..... 242
 - in Hs578T human breast cells..... 238
- ChromatinDB database..... 218–219, 222, 224
- Chromatin endogenous cleavage (ChEC)
 - with psoralen photocrosslinking
 - (ChEC/psoralen assay), 292
- Chromatin fragmentation
 - enzymatic chromatin fragmentation..... 348
 - using a probe sonicator 347
 - using a sonication bath 347–349
- Chromatin immunocleavage (ChIC) 296
- Chromatin immunoprecipitation (ChIP)
 - for analysis of the bound DNA by cloning (ChIP
 - cloning)..... 97
 - cross -linked ChIP (XChIP)
 - disuccinimidyl glutarate (DSG)..... 177
 - formaldehyde 177
 - in cultured primary hippocampal neurons 361–362
 - with DNA microarray (ChIP-chip)
 - affymetrix gene chip system..... 6
 - DNA amplification and labeling 8, 15
 - with DNA sequencing (ChIP-seq)
 - heliscope single molecule sequencing platform
 - (Helicos) 158
 - Illumina Solexa genome analyzer 6
 - in *Drosophila melanogaster* 10
 - histone citrullination..... 482–484

Chromatin immunoprecipitation (ChIP) (*Continued*)
 in human U-937 macrophages 122–123, 125
 in human umbilical vein endothelial cells
 (HUVECs) 205
 in LNCaP cells 164
 in mouse embryos 86, 336
 in mouse hippocampal cells 357–359
 in mouse hippocampal neurons by enzymatic
 hippocampal cell dissociation 360
 with paired-end ditag (ChIP-PET) 97
 Circularization of linker-ligated cDNA fragments 543
 Confocal microscopy 508, 522–526, 530
 Core factor purification 584–585
 COS-7 cells 76
 CPDs. *See* Cyclobutane pyrimidine dimers
 cRNA
 purification 513
 synthesis 513, 514
 CsCl buoyant density ultracentrifugation 4
 Cutaneous T cell lymphoma (CTCL)
 Hut-78 cells 50, 54
 Cyclic AMP (cAMP) 201–214
 Cyclobutane pyrimidine dimers (CPDs) 303, 304,
 307, 309, 317

D

dA-tailing 117
 Dimethyl apidimidate (DMA) 109, 145
 Disuccinimidyl glutarate (DSG) 106–110,
 19, 169, 177, 180, 184, 185
 DMA. *See* Dimethyl apidimidate
 DNA
 cross-linking using azido-benzoyl
 and phosphorothioate 394
 footprinting 82, 279, 382–384,
 388–389, 391–394, 397
 nick repair 553, 554
 for nucleosome reconstitution 369–370,
 374–375, 383, 385, 389, 396, 398
 probe synthesis by PCR and nucleosome reconstitution .
 383, 389
 DSG. *See* Disuccinimidyl glutarate
 Dynalbeads M280 Streptavidin 544

E

EAF6 (orthlog of *Esa1*-associated factor 6) 447
 EcoP15I digestion 543, 553
 Electrophoretic mobility shift assay (EMSA)
 in HeLa cells
 anti-HIP116/SMARCA3, 66
 anti-Pol II clone 8WG16, 66
 anti-TBP 1/mAb2C1, 66
 anti-TBP 2/mAb4C2, 66
 anti-TBP 3/mAb3G3, 66

anti-TLS/FUS/mAb1D2, 66
 HA antibody 192
 in Hut-78 cells 50, 54, 55
 Elongation rate 269, 580, 586–588
 Embryos
Drosophila melanogaster 10
 EMSA. *See* Electrophoretic mobility shift assay
 Epac. *See* Exchange protein directly activated by cAMP
 ES cells 412, 415
 EvaGreen 151, 153, 155
 Exchange protein directly activated by cAMP
 (Epac) 201–214
 Exoribonuclease
 Rat1p 594, 596, 604
 Rrp6p 596, 599
 Xrn1p 596, 604

F

Factor Chromatin Association 276
 FeBABE
 to DNA and nucleosomes 387–
 Fe-EDTA 382
 Flavopiridol 269, 271, 275
FLR1 29–32, 38–46
 Fluorine-conjugated UTP (FUrd) 521–525,
 528, 530

G

Gel-purification
 of ligation products 118
 General transcription factor (GTF) 64, 70, 149, 427
 GsuI digestion 550
 GTF. *See* General transcription factor

H

HAT. *See* Histone acetyltransferase
 HEK293 cells 77, 433, 439, 440
 Heliscope single molecule sequencing platform
 (Helicos) 4, 158, 159, 167
 HIF. *See* Hypoxia-inducible factor
 Histone
 acetylation 224–264
 arginine methylation 473 found in abstract
 citrullination 473–487
 demethylase 411, 414, 421–425
 H3 H4, 255
 nucleosomes 177, 218, 263, 321,
 335, 367, 374, 376, 381, 382, 385–387, 396,
 398–399, 401, 404, 405, 407, 423, 424, 428, 473
 octamers with site-specific cysteines 385
 Histone acetyltransferase (HAT)
 GCN5 428–429, 431,
 433, 437, 446
 two-step purification 431

Histone citrullination
 assay with HL-60 cells 479–480
 by immunostaining 480
 by western blotting 479–480

Histone methyltransferase (HMT)
 MLL3 (mixed-lineage leukemia 3) 467
 MLL4 (mixed-lineage leukemia 4) 465, 467
 PA1 467

HIV core promoter 65, 69

HMT. *See* Histone methyltransferase

Hydroxyl radical DNA footprinting 383–384,
 392, 394

Hypoxia-inducible factor (HIF) 189–199

I

IFN- γ 87, 88, 92

I κ B α 49–61, 121–133

Illumina array hybridization 513

Illumina Solexa genome analyzer
 sample preparation 6, 9–10

Immuno-depletion
 of p90RSK in cell lysate 78, 80

Immunofluorescence
 antibody against BrdU 524
 antibody against the Upstream Binding Factor
 (UBF) 524

Immunoprecipitation
 anti-acetyl-histone H3 (Lys14) 257
 anti-AR N20 163
 anti-C/EBP β 204, 208
 anti-HA 155
 anti-H3Cit 483
 anti-histone H3 257
 anti-histone H4 257
 anti-H3R17Me 478
 anti-hyperacetylated histone H4 (Penta) 257
 anti-myc 155
 anti-PAD4 478, 483
 β -actin IP as a negative control 419
 I κ B α 121–133
 NF κ B p50 122–126
 NF κ B p65 122–123, 125, 126
 normal mouse IgG 567, 570

Immunostaining
 of *Drosophila* polytene chromosomes 267–276

Indirect end labeling
 to observe nucleosome movement in vivo 368

ING5 (inhibitor of growth 5) 447, 449–451,
 454, 456–459, 462

In-gel kinase assay 76, 77, 79–83

In silico analyses
 YEASTRACT
 MUSA algorithm 28

Iodination 385, 399–402, 404, 407, 408

ISW2 368, 382, 392–394,
 396–398, 404, 407

K

KAT activity 446, 457–459, 462

Klenow DNA polymerase 18, 163, 168, 383

L

lacZ fusion 30, 35–37, 39–43

Leptomycin B (LMB) 122, 123, 125–128, 132
 to induce nuclear I κ B α in human U-937
 macrophages 122

M

Magnetic beads
 Dynabeads^{TM1} 41, 144
 Protein G 88, 94, 98, 141,
 142, 280, 281, 284, 355

Methyl-binding protein 2 (Mecp2) 141

Methylene blue stain 595, 597

Micrococcal Nuclease (MNase) 93, 176, 177,
 221, 222, 226, 231, 233, 292–294,
 296, 297, 300, 322–329, 362, 368,
 371, 372, 379, 421, 425, 478, 482,
 483, 485, 486
 fused to the target protein 292

Microdissection 140
 hypothalamic nucleus paraventricularis (PVN) from the
 mouse brain 143

Mini-BeadBeater 150, 152

MNase. *See* Micrococcal Nuclease

MOZ-related factor (MORF) 428, 447–451,
 454, 456–459, 462

N

NER. *See* Nucleotide excision repair

Neurospheres from ESCs 416

Next generation sequencing (NGS) 106, 110,
 116–119, 160, 273, 274, 535–562

NFAT 75–84, 91

NF κ B 49–61, 121–133
 p65 and p50 122, 123, 125, 127

NGS. *See* Next generation sequencing

Northern blot 492, 595, 597–599,
 604, 606, 612, 614–616, 620

Nucleosome
 movement by gel shift assays 371, 378–379
 position and movement in-vitro by site-directed
 mapping 369–371, 374–378
 reconstitution 369–370, 374–375, 383,
 385, 389, 396–398, 407, 428, 450, 458, 459
 scanning 321–331

Nucleotide excision repair (NER), 304, 308

O

Oligonucleotide DNA affinity purification
in COS-7 cells.....76
in 3T3/L1..... 76, 77, 81
Oxidation of diol structures..... 538–359, 547

P

PAD4. *See* Peptidylarginine deiminase 4
Paired end tag analysis for full-length mRNA (RNA-PET)
clustering and genome annotation..... 558–560
mapping of the paired end tags (PETs) 544, 554,
557–560
sequencing with Illumina (Solexa)
GA and SOLiD v4..... 557–558
Papain/Trypsin digestion.....360
Peptidylarginine deiminase 4 (PAD4).....474–479, 481,
483–485
Phoenix-Ampho retrovirus.....467
Phorbol 12-myristate 13-acetate (PMA) 76–80, 123,
126–128
induce differentiation of U-937 cells into
macrophages 127
Phosphorothioate-DNA..... 387, 405
PIC. *See* Pre-initiation complex (PIC)
PMA. *See* Phorbol 12-myristate 13-acetate
pncRNA. *See* Promoter-associated noncoding RNA
Pol II. *See* RNA polymerase II
Polytene chromosomes 26–277
Pre-initiation complex (PIC)..... 63–73, 108, 110, 111, 160
p90 ribosomal S6 kinase (RSK)..... 77–79, 81
Primer design 114, 140, 145, 155, 573
Primer3..... 155
Promoter-associated noncoding RNA
(pncRNA)..... 609–621
interaction with TLS..... 616–619
Proteasome 50, 54, 60, 122, 189, 227–230
inhibitor MG132..... 50
p70 S6 kinase (S6K)..... 79, 81
Psoralen photocrosslinking..... 292, 294–298

Q

Quantitative Real-Time Genomic PCR
(Q-RT-gPCR).....109–111, 114, 115
Quantitative real-time PCR
normalization primers
intergenic chromosome V region.....286
PHO5.....286
PHO5-TATA..... 323

R

Radioactive labelling..... 65–68, 71
of oligonucleotides..... 65, 67–68

rDNA. *See* ribosomal DNA
Real-time polymerase chain reaction..... 31–32,
43–45, 47, 91, 92, 96, 101, 114, 115, 117,
125, 126, 128, 131–132, 137, 145, 151, 153,
163, 166, 167, 183, 190, 191, 193–195, 209,
241, 247, 257, 261, 262, 279–288, 323–324,
328–331, 354, 359, 478, 484, 486, 514, 573,
574, 603–605, 611, 612, 615, 618

Restriction enzyme-digestion
*Eco*RI..... 308, 311
*Hind*III 308, 312
*Nhe*I..... 308, 312
Reverse transcription of RNA 191, 193–194
random hexamer primer (Fermentas) 191
Ribonuclease protection assay (RPA) 491–502
phosphoimaging 492, 500
Ribosomal DNA (rDNA)291–294, 304, 305,
307–309, 311, 312, 318, 581, 582, 586
Ribosomal RNA (rRNA)291–301, 304,
307–309, 315, 492, 520–522, 530, 579, 585, 606

RNA

abundance..... 287, 491–502, 506, 516, 560
extraction.....32, 44, 198, 496–498, 594–597, 612, 618
gel-shift assay 611–614, 616–618
labeling507, 510–511, 617
probes..... 492, 493, 498–501, 614, 620
splicing275, 474, 492, 564
stability491–502, 505,
563, 594

RNA-chromatin immunoprecipitation
(RNA-ChIP)..... 563–576
RNA polymerase I..... 291, 293, 304, 520, 579–590
purification 580–581
RNA polymerase II (Pol II).....63–73, 145, 146,
268, 269, 271, 272, 275, 287, 340, 427, 520,
564–566, 594

phosphorylation level..... 271, 275
RNase III..... 594, 596
Rnt1p..... 594, 596
ROS..... 484, 485
by flow cytometry 484–485
ROX (5-(and-6)-carboxyrhodamine 6G
succinimidyl ester)151, 153, 154,
191, 194, 198, 281, 286

RPA. *See* Ribonuclease protection assay
rRNA. *See* ribosomal RNA
RSK. *See* p90 ribosomal S6 kinase
Run-on transcription assay..... 520–522, 524–525
HeLa cells..... 521, 524

S

Saccharomyces cerevisiae28–31, 37–39, 41,
43, 140, 217, 218, 256, 280, 292, 304, 322, 324,
367, 402

- Sf9 insect cells425, 448, 451, 460
 si RNA. *See* small inhibitory RNA
 Site-directed mapping 368–371, 374–378
 that maps nucleosome movement with single base pair
 (bp) resolution..... 368
 Site-directed mutagenesis.....30, 34–37, 39, 43, 398
 S6K. *See* p70 S6 kinase
 Small inhibitory RNA (siRNA) 202, 205, 209–211, 213,
 214, 252, 611, 614, 616, 619, 620
 Epac1 202, 205, 213
 Hut–78 cells 50, 54, 55
 I κ B α50, 51, 54–56, 60
 SOCS–3 202, 205, 209–211, 213, 214
 umbilical vein EC (HUVEC)202, 203, 205, 207,
 209–214
 SOCS–3. *See* Suppressor of cytokine signalling–3 (SOCS–3)
 Soluble chromatin 152, 425, 601–602, 619, 620
 Southern blotting295, 298–301, 304,
 315, 322, 369, 371, 373
 S-Sepharose Resin..... 437–439
SUC2 262, 321–331
 induction322, 324, 326, 329, 330
 Suppressor of cytokine signalling–3 (SOCS–3) 201–214
 SWI/SNF.....322, 324, 330, 368,
 382, 386–388, 394, 402–404, 406
 interactions with nucleosomes..... 387–388
 SYBR Gold 10, 19, 386, 400, 402, 403
 SYBR Green..... 10, 20, 31, 45, 89, 96, 114,
 116, 137, 142, 145, 163, 191, 194, 198, 209, 257,
 261, 262, 281, 286, 323, 328, 331, 478, 486, 542,
 544, 545, 567, 604
- T**
- Tata Binding Protein Purification 583–584
 T4-endonuclease-V enzyme..... 304, 305,
 312, 313
 3T3/L1 cells 76, 77, 81
 TLS. *See* Translocated in liposarcoma
 Transcription
 elongation269, 275, 505, 519–521,
 529, 579–590, 594
 factors.....3–24, 28–30,
 39–42, 46, 64, 76, 82, 87, 95–97, 100,
 101, 106, 149, 157, 162, 164, 175–177,
 186, 189, 220, 222–224, 226–228, 427,
 505, 579, 580, 582, 586, 589, 594
 inhibition 50, 54, 121, 122, 132, 211,
 252, 521
 Translocated in liposarcoma (TLS) 66, 610,
 611, 614–619
- U**
- UAF purification 582, 585
 U2OS cell treatment..... 482, 484
 UV irradiation298–300, 304–305, 307,
 309–311, 403, 404, 476, 614
- V**
- Vascular endothelial growth factor
 (VEGF)..... 190, 191, 194, 195, 197, 203
 von Hippel-Lindau (VHL) tumor
 suppressor protein..... 189
- W**
- Western blotting
 actin rabbit polyclonal antibody..... 53
 anti-H3Cit 479, 480
 Calmodulin Binding Peptide (CBP) tag..... 240
 I κ B α rabbit polyclonal antibody..... 53
- X**
- Xenopus laevis*385, 392, 398, 405
- Y**
- Yeast
 extract/peptone/dextrose (YPD) media.....256
 Peptone Adenine Dextrose (YPAD) 294
- Z**
- Zirconium grinding beads 280, 283